CDXS vs DHR vs GRFS Stock Comparison

Codexis, Danaher and Grifols Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (TECH) Create a free account to keep reading and compare up to 10 companies.
CDXS Codexis, Inc.
$1.28 -3.0% 1M -50.8% 1Y
Market cap
$116.98M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
DHR Danaher Corp /De/
$232.08 +3.3% 1M +5.0% 1Y
Market cap
$163.13B
P/E
40.9x
Revenue (TTM)
$25.11B
Div. yield
0.65%
Life Sciences Tools Healthcare
7 wins
GRFS Grifols SA
$8.10 +10.2% 1M -13.6% 1Y
Market cap
$5.51B
P/E
12.1x
Revenue (TTM)
—
Div. yield
1.36%
Biotechnology Healthcare
3 wins

Head to Head

12 decided of 12

Danaher leads on 7 of the 12 questions below (Danaher 7, Grifols 3, Codexis 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCDXSDHRGRFSLeader
Larger companyMarket capitalisation $116.98M $163.13B $5.51B DHR
Cheaper on earningsLower P/E, profitable companies only -3.8x 40.9x 12.1x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 25.5x 8.6x GRFS
Faster revenue growthRevenue growth, trailing twelve months +35.9% +4.6% — CDXS
More profitableNet margin, trailing twelve months -39.6% 15.9% — DHR
Better return on capitalReturn on invested capital -35.1% 5.7% — DHR
Less leveragedLower net debt / EBITDA 0.7x 2.9x — CDXS
Higher dividend yieldTrailing dividend yield — 0.65% 1.36% GRFS
Better 1-year returnPrice return, last 12 months -50.8% +5.0% -13.6% DHR
Better 5-year returnAnnualised price return, 5 years -48.4%/yr -5.3%/yr -9.4%/yr DHR
Less volatileAnnualised volatility, 1 year 86.7% 30.6% 32.4% DHR
Higher overall scoreMean of the five percentile scores vs peers 45/100 59/100 56/100 DHR

Percentile Scorecard

CDXSDHRGRFS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCDXSDHRGRFS
Valuation 40 #137 of 227 67 #76 of 227 99 #7 of 625
Growth 67 #73 of 219 21 #174 of 219 –
Profitability 43 #117 of 206 88 #25 of 206 –
Financial Health 30 #166 of 238 46 #129 of 238 14 #564 of 656
Shareholder Returns 42 #78 of 134 75 #34 of 134 56 #161 of 365
Overall 45 59 56
  • CDXS ranked among 247 companies in Medical Devices and Diagnostics
  • DHR ranked among 247 companies in Medical Devices and Diagnostics
  • GRFS ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCDXSDHRGRFSSPY
1 month -3.0%+3.3%+10.2% -0.2%
3 months -14.7%+16.6%+1.2% +3.9%
6 months -54.6%+29.7%+0.4% +8.2%
Year to date -21.5%+1.4%-13.4% +12.9%
1 year -50.8%+5.0%-13.6% +12.3%
3 years -17.4%+23.5%+3.3% +87.4%
3 years, per year -6.2%+7.3%+1.1% +23.3%
5 years -96.3%-23.8%-39.0% +67.9%
5 years, per year -48.4%-5.3%-9.4% +10.9%
10 years -71.6%+196.3%-44.7% +261.1%
10 years, per year -11.8%+11.5%-5.8% +13.7%

Risk

MeasureCDXSDHRGRFSSPY
Volatility, 1Y 86.7%30.6%32.4% 12.7%
Downside volatility, 1Y 91.1%31.6%34.1% 12.7%
Beta vs S&P 500, 1Y 1.850.450.95 1.00
Return / volatility, 1Y -0.590.16-0.42 0.97
Max drawdown, 5Y -97.7%-50.8%-58.8% -25.4%
From 52-week high -55.1%-4.1%-16.7% -1.2%
52-week high $2.85$242.05$9.72 $779.14
52-week low $0.98$161.91$7.02 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCDXSDHRGRFS
P/E now vs peer median -3.8xmedian 29.6x 40.9xmedian 29.6x 12.1xmedian 17.2x
P/S now vs peer median 1.5xmedian 2.9x 6.5xmedian 2.9x 0.6xmedian 9.0x
EV/EBITDA now vs peer median -4.9xmedian 17.4x 24.2xmedian 17.4x —median 16.3x
P/FCF now vs peer median -9.6xmedian 22.3x 29.8xmedian 22.3x 7.8xmedian 18.7x
P/B now vs peer median 3.5xmedian 2.3x 3.1xmedian 2.3x 0.6xmedian 2.2x
PEG now vs peer median -0.14median 1.04 -3.26median 1.04 —median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCDXSDHRGRFS
Revenue $77.68M $25.11B –
Gross profit $67.60M $14.69B –
Operating income -$27.66M $5.13B –
Net income -$30.72M $4.00B –
Free cash flow -$12.18M $5.47B –
R&D $48.74M $1.62B –
EPS (diluted) $-0.34 $5.66 –
Cash & equivalents $27.17M $4.35B $969.15M
Total debt $40.88M $26.56B $44.00B
Shares (diluted) 91.05M 707.60M 681.57M
Enterprise value -$140.07M $146.95B $4.59B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCDXSDHRGRFS
P/E -3.8x 40.9x 12.1x
P/FCF -9.6x 29.8x 7.8x
P/Operating cash flow -11.2x 24.6x –
P/S 1.5x 6.5x 0.6x
P/B 3.5x 3.1x 0.6x
P/Tangible book 3.5x 5.2x 1.0x
EV/EBITDA -4.9x 24.2x –
EV/EBIT -3.7x 36.1x –
EV/Revenue 1.3x 7.4x –
EV/FCF -8.5x 33.9x –
EV/Operating cash flow -9.9x 27.9x –
PEG (3Y EPS CAGR) -0.14 -3.26 –

Growth

14 metrics
MetricCDXSDHRGRFS
Revenue growth (1Y) 35.9% 4.6% –
Revenue CAGR (3Y) -7.8% -0.5% –
Gross profit growth (1Y) 52.4% 2.6% –
Gross profit CAGR (3Y) -2.6% -0.9% –
Operating income growth (1Y) 51.7% 16.1% –
Operating income CAGR (3Y) 22.8% -7.1% –
Net income growth (1Y) 52.7% 17.3% –
Net income CAGR (3Y) 18.5% -14.3% –
EPS growth (1Y) 55.7% 19.2% –
EPS CAGR (3Y) 26.2% -12.5% –
Operating cash flow growth (1Y) 83.0% 7.6% –
Operating cash flow CAGR (3Y) -152.3% -7.6% –
Free cash flow growth (1Y) 82.0% 12.4% –
Free cash flow CAGR (3Y) -26.3% -9.0% –

Profitability

14 metrics
MetricCDXSDHRGRFS
Gross margin 87.0% 58.5% –
EBITDA margin -27.0% 30.5% –
Operating margin -35.6% 20.4% –
Pretax margin -39.5% 19.0% –
Net margin -39.6% 15.9% –
FCF margin -15.7% 21.8% –
Operating cash flow margin -13.4% 26.4% –
Return on equity -80.6% 7.6% –
Return on assets -24.6% 4.5% –
Return on invested capital -35.1% 5.7% –
Return on capital employed -27.3% 6.4% –
Asset turnover 0.6x 0.3x –
Cash conversion (OCF / net income) 0.3x 1.7x –
Stock comp / revenue 9.9% 1.2% –

Financial Health

11 metrics
MetricCDXSDHRGRFS
Debt / assets 34.0% 28.8% 48.9%
Debt / equity 1.2x 0.5x 1.3x
Net debt / EBITDA 0.7x 2.9x –
Debt / FCF -3.4x 4.9x –
Liabilities / assets 72.5% 43.1% 61.4%
Equity / assets 27.5% 56.9% 38.6%
Interest coverage – 17.6x –
Current ratio 3.1x 1.7x 2.5x
Quick ratio 2.9x 1.0x 0.8x
Cash ratio 2.3x 0.5x 0.4x
Altman Z-score -6.14 3.72 –

Shareholder Returns

7 metrics
MetricCDXSDHRGRFS
Dividend yield – 0.7% 1.4%
Net buyback yield -0.3% 1.8% –
Shareholder yield -0.3% 2.4% 1.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCDXSDHRGRFS
Forward P/E – 25.5xFY2026 8.6xFY2026
EPS, next fiscal year $-0.37FY2026 $9.11FY2026 $0.94FY2026
EPS growth, next FY – +16.8%FY2026 +10.6%FY2026
EPS growth, the year after – +8.0% +26.6%
Revenue, next fiscal year $77.93MFY2026 $27.01BFY2026 $8.88BFY2026
Revenue growth, next FY +10.7%FY2026 +9.9%FY2026 +0.0%FY2026
Revenue growth, the year after +9.2% -1.9% +10.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCDXSDHRGRFS
Held by institutions 71.0% 81.9% 21.0%
Institutions holding 148 2,116 166
Change in shares held, QoQ -2.4% +1.1% -0.5%
Institutions buying 88 838 73
Institutions selling 36 1,015 65
Buyers to sellers 2.44 0.83 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CDXSDHRGRFS
CDXS 1.00 0.07 0.17
DHR 0.07 1.00 0.20
GRFS 0.17 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CDXS, DHR and GRFS?

Danaher (DHR) is the largest by market capitalisation: Codexis (CDXS) $116.98M, Danaher (DHR) $163.13B, Grifols (GRFS) $5.51B.

Which stock is cheaper, CDXS, DHR and GRFS?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Codexis (CDXS) -3.8x, Danaher (DHR) 40.9x, Grifols (GRFS) 12.1x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Danaher (DHR) 25.5x, Grifols (GRFS) 8.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Codexis (CDXS) +35.9%, Danaher (DHR) +4.6%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Codexis (CDXS) -39.6%, Danaher (DHR) 15.9%). On return on invested capital, Danaher (DHR) leads (Codexis (CDXS) -35.1%, Danaher (DHR) 5.7%).

Which stock has performed better?

Over the past year Danaher (DHR) returned the most: Codexis (CDXS) -50.8%, Danaher (DHR) +5.0%, Grifols (GRFS) -13.6%. Over five years, Danaher (DHR) compounded fastest (Codexis (CDXS) -48.4%/yr, Danaher (DHR) -5.3%/yr, Grifols (GRFS) -9.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Grifols (GRFS) has the highest dividend yield: Danaher (DHR) 0.65%, Grifols (GRFS) 1.36%. Codexis (CDXS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Codexis (CDXS) 86.7%, Danaher (DHR) 30.6%, Grifols (GRFS) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CDXS, DHR and GRFS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.